Company profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was
- CEO
- Dr. Christopher J. Kirk Ph.D.
- Headquarters
- South San Francisco, CA, United States
- Employees
- 9
- IPO date
- Jun 21, 2018
- Sector
- Healthcare
- Industry
- Biotechnology